The cancer immunotherapy developer has added $37m to increase a series C round featuring Celgene and Alphabet unit GV to $97m.
US-based small molecule drug developer Rapt Therapeutics has closed a $37m extension to a series C round backed by internet and technology conglomerate Alphabet and pharmaceutical company Celgene that now stands at $97m.
T. Rowe Price Associates, The Column Group (TCG), Kleiner Perkins and Topspin Partners also took part in the extension, with Alphabet participating through early-stage investment unit, GV. All the investors previously contributed to the round’s $60m first tranche in December 2017.
Formerly known as FLX Bio,…
